Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
PAION AG / Schlagwort(e): Insolvenz PAION AG: Insolvenzplan wird erstellt / Aktionäre sollen sämtliche Aktien kompensationslos verlieren 28.08.2024 / 15:28 CET/CEST Veröffentlichung einer...
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) will hold a conference call on Monday, 22nd November 2010 at 10.00 am...
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that it will be present at the following conferences:...
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the...
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today reported its consolidated financial result according to...
PAION AG hereby announces that the following financial reports shall be disclosed: Report: Financial report of the group for the first half-year 2009Date of disclosure 05...
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today reported its consolidated financial result according to...
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) and ERGOMED Clinical Research Limited today announce data from the...
PAION AG hereby announces that the following financial reports shall be disclosed: Report: Annual financial report 2008 (PAION AG and Group) Date of disclosure: 17 March...
Announcement according to ? 15 WpHG: Disclosure announcement transmitted by Business Wire. The issuer is responsible for the content of this announcement...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
